Search

Your search keyword '"Minucci, Saverio"' showing total 724 results

Search Constraints

Start Over You searched for: Author "Minucci, Saverio" Remove constraint Author: "Minucci, Saverio" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
724 results on '"Minucci, Saverio"'

Search Results

4. Author Response: Automated workflow for the cell cycle analysis of non-adherent and adherent cells using a machine learning approach

5. Automated workflow for the cell cycle analysis of non-adherent and adherent cells using a machine learning approach

11. Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models

13. Biocompatible cellulose nanocrystal-based Trojan horse enables targeted delivery of nano-Au radiosensitizers to triple negative breast cancer cells.

16. Automated workflow for the cell cycle analysis of non-adherent and adherent cells using a machine learning approach

17. Inhibition of the lysine demethylase LSD1 modulates the balance between inflammatory and antiviral responses against coronaviruses

18. LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+T cell responsiveness

20. Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms

21. Corrigendum: The Polycomb group proteins bind throughout theINK4A-ARFlocus and are disassociated in senescent cells

23. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles

25. Supplementary Methods from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

26. Data from In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype

27. Supplementary Tables S1-S6, S17-S18 from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

28. SupplementaryTables S7-S16 from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

29. Supplementary Methods, Figures 1 - 3, Tables 1 - 3 from Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

30. Supplementary Tables S1 - S5 from In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype

31. Supplementary Methods, Figure Legends from In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype

32. Supplementary Figures from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

33. Data from Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

34. Supplementary Figures S1 - S8 from In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype

35. Supplementary Table 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

36. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

37. Supplementary Figure 3 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

38. Supplementary Figure 5 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

39. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

40. Suppl. Methods from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

41. Supplementary Figure 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

42. Supplementary Figure 2 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

43. Supplementary Figure 8 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

44. Figure S1 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

45. Supplementary Figure 4 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

46. Supplementary Table 1 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

47. Supplementary Figure 6 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

48. Legends of supplementary figure 1 and 2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

49. Supplementary Figure 7 from c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Catalog

Books, media, physical & digital resources